The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma

Respiratory Medicine

Volumn 106, Issue 1, 2012, Pages 34-46

  Wasfi, Yasmine S ^a   Villarán, César ^b   De Tilleghem, Celine Le Bailly ^a   Smugar, Steven S ^a   Hanley, William D ^a   Reiss, Theodore F ^a   Knorr, Barbara A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b CLÍNICA RICARDO PALMA   (Peru)

Author keywords

5 Lipoxygenase; Asthma; Leukotrienes

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; PLACEBO; SETILEUTON;

ADULT; AGED; ARTICLE; ASTHMA; BASAL CELL CARCINOMA; CHRONIC CHOLECYSTITIS; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EOSINOPHIL; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; GASTROENTERITIS; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SINUSITIS;

ADOLESCENT; ADULT; AGED; ASTHMA; BENZENESULFONATES; BENZOPYRANS; CHRONIC DISEASE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LEUKOTRIENE B4; LIPOXYGENASE INHIBITORS; MALE; MIDDLE AGED; OXADIAZOLES; SPIROMETRY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82955198481     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2011.08.019     Document Type: Article

References (32)

1. L. Cazzoletti, A. Marcon, C. Janson, A. Corsico, D. Jarvis, and I. Pin Asthma control in Europe: a real-world evaluation based on an international population-based study J Allergy Clin Immunol 120 2007 1360 1367 (Pubitemid 350225685)
2. B. Stallberg, K. Lisspers, M. Hasselgren, C. Janson, G. Johansson, and K. Svardsudd Asthma control in primary care in Sweden: a comparison between 2001 and 2005 Prim Care Respir J 18 2009 279 286
3. E.D. Bateman, H.A. Boushey, J. Bousquet, W.W. Busse, T.J. Clark, and R.A. Pauwels Can guideline-defined asthma control be achieved? The gaining optimal asthma control study Am J Respir Crit Care Med 170 2004 836 844 (Pubitemid 39346477)
4. R.L. Cowie, M.F. Underwood, D.D. Sin, H.M. Sharpe, N.R. Bell, and S.F. Man Asthma control and management in the community: indices in 1997 compared with indices in 2002 Can Fam PhysicianCan Fam Physician 52 2006 750 751 (Pubitemid 44406058)
5. M. Peters-Golden, and W.R. Henderson Jr. Leukotrienes N Engl J Med 357 2007 1841 1854
6. A.P. Sampson FLAP inhibitors for the treatment of inflammatory diseases Curr Opin Investig Drugs 10 2009 1163 1172
7. A.M. Tager, S.K. Bromley, B.D. Medoff, S.A. Islam, S.D. Bercury, and E.B. Friedrich Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment Nat Immunol 4 2003 982 990 (Pubitemid 37265919)
8. A. Hicks, S.P. Monkarsh, A.F. Hoffman, and R. Goodnow Jr. Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments Expert Opin Investig Drugs 16 2007 1909 1920 (Pubitemid 351403723)
9. N. Miyahara, S. Miyahara, K. Takeda, and E.W. Gelfand Role of the LTB4/BLT1 pathway in allergen-induced airway hyperresponsiveness and inflammation Allergol Int 55 2006 91 97 (Pubitemid 43973880)
10. S.E. Wenzel, S.J. Szefler, D.Y. Leung, S.I. Sloan, M.D. Rex, and R.J. Martin Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids Am J Respir Crit Care Med 156 1997 737 743 (Pubitemid 27396409)
11. A. Jatakanon, C. Uasuf, W. Maziak, S. Lim, K.F. Chung, and P.J. Barnes Neutrophilic inflammation in severe persistent asthma Am J Respir Crit Care Med 160 1999 1532 1539
12. J. Shannon, P. Ernst, Y. Yamauchi, R. Olivenstein, C. Lemiere, and S. Foley Differences in airway cytokine profile in severe asthma compared to moderate asthma ChestChest 133 2008 420 426 (Pubitemid 351272400)
13. M.C. Liu, L.M. Dube, and J. Lancaster Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton study group J Allergy Clin Immunol 98 1996 859 871 (Pubitemid 26405886)
14. W. Berger, M.T. De Chandt, and C.B. Cairns Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease Int J Clin PractInt J Clin Pract 61 2007 663 676 (Pubitemid 46449830)
15. Standardization of Spirometry, 1994 Update American thoracic society Am J Respir Crit Care Med 152 1995 1107 1136
16. E.F. Juniper, G.H. Guyatt, P.J. Ferrie, and L.E. Griffith Measuring quality of life in asthma Am Rev Respir Dis 147 1993 832 838 (Pubitemid 23093803)
17. E.F. Juniper, P.M. O'Byrne, G.H. Guyatt, P.J. Ferrie, and D.R. King Development and validation of a questionnaire to measure asthma control Eur Respir J 14 1999 902 907 (Pubitemid 29519356)
18. R.G. Price Measurement of N-acetyl-beta-glucosaminidase and its isoenzymes in urine methods and clinical applications Eur J Clin Chem Clin Biochem 30 1992 693 705
19. Expert panel report 3: guidelines for the diagnosis and management of asthma 2007
20. GINA report: global strategy for asthma management and prevenion 2009 (update) 2009
21. T.F. Reiss, J.B. Hill, E. Harman, J. Zhang, W.K. Tanaka, and E. Bronsky Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist Thorax 52 1997 1030 1035 (Pubitemid 27515780)
22. S.A. Green, M.P. Malice, W. Tanaka, C.A. Tozzi, and T.F. Reiss Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation Thorax 59 2004 100 104 (Pubitemid 38223478)
23. N. Rabinovitch, L. Zhang, and E.W. Gelfand Urine leukotriene E4 levels are associated with decreased pulmonary function in children with persistent airway obstruction J Allergy Clin Immunol 118 2006 635 640 (Pubitemid 44301392)
24. C. Cai, J. Yang, S. Hu, M. Zhou, and W. Guo Relationship between urinary cysteinyl leukotriene E4 levels and clinical response to antileukotriene treatment in patients with asthma Lung 185 2007 105 112 (Pubitemid 46571872)
25. S.E. Dahlen, K. Malmstrom, E. Nizankowska, B. Dahlen, P. Kuna, and M. Kowalski Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial Am J Respir Crit Care Med 165 2002 9 14 (Pubitemid 34053350)
26. N. Rabinovitch, N.J. Graber, V.M. Chinchilli, C.A. Sorkness, R.S. Zeiger, and R.C. Strunk Urinary leukotriene E4/exhaled nitric oxide ratio and montelukast response in childhood asthma J Allergy Clin Immunol 126 2010 545 551
27. E. Israel, P. Rubin, J.P. Kemp, J. Grossman, W. Pierson, and S.C. Siegel The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma Ann Intern Med 119 1993 1059 1066 (Pubitemid 23359918)
28. R.L. Bell, P.R. Young, D. Albert, C. Lanni, J.B. Summers, and D.W. Brooks The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor Int J Immunopharmacol 14 1992 505 510
29. E. Israel, J. Cohn, L. Dube, and J.M. Drazen Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. zileuton clinical trial group JAMA 275 1996 931 936 (Pubitemid 26095384)
30. J.A. Bernstein, N. Liu, B.A. Knorr, S.S. Smugar, W.D. Hanley, and T.F. Reiss MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease Respir Med 105 2011 392 401
31. S.C. Lazarus, T. Lee, J.P. Kemp, S. Wenzel, L.M. Dube, and R.F. Ochs Safety and clinical efficacy of zileuton in patients with chronic asthma Am J Manag Care 4 1998 841 848 (Pubitemid 28375894)
32. P.B. Watkins, L.M. Dube, K. Walton-Bowen, C.M. Cameron, and L.E. Kasten Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma Drug Saf 30 2007 805 815 (Pubitemid 47347353)